ArticleScientific reports2026
The miR-181d-5p/SPP1 axis inhibits the migration and invasion of colorectal cancer via the RhoA patyway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Disease-Specific Panel of Salivary microRNAs for the Detection of Oral Squamous Cell Carcinoma from Early Invasion to Stage IV Disease.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC), as the most common malignant tumor, seriously threatens human’s life and safety. Evidence suggests that microRNAs (miRNAs) exhibit an essential role in regulating the occurrence and development of CRC, while the detailed effects and possible mechanisms remain to be further explored. In the present study, a new tumor suppressor function of miR-181d-5p was disclosed in CRC. The expression of miR-181d-5p was obviously decreased in CRC tissues and cell lines. In addition, up-regulation of miR-181d-5p suppressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT) progress in CRC cells detected by cell transfection, CCK-8, wound healing, transwell migration and western blot assays. Moreover, secreted phosphoprotein 1 (SPP1) was verified as a direct target of miR-181d-5p by binding its 3’-UTR, and confirmed by dual-luciferase reporter assay. Additionally, SPP1 was remarkably increased in CRC tissues and CC cell lines, and was negatively associated with miR-181d-5p expression. Furthermore, over-expression of SPP1 partially restored the inhibitory effects of up-regulated miR-181d-5p on cell viability, migration and EMT progress in CRC cells by modulating RhoA pathway. Finally, up-regulated miR-181d-5p inhibited the tumorigenesis in nude mice by regulating SPP1 mediated with RhoA pathway. To conclude, miR-181d-5p might serve as an effective target for the treatment of patients with CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.